美国 · SEC FORM 4
MiNK Therapeutics, Inc.
INKT · Nasdaq · CIK 0001840229 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
14 同一窗口内观察到的 Form 4 交易行
3 sales · 11 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2023-10-16 · AGENUS INC.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 49,583
- 上期报告
- 57,136
- 日均成交量
- 15,898
- 回补天数
- 3.1
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2023-10-16 | AGENUS INC | 买入 (P) | Common Stock | 429 | USD 1.10 | USD 472 | SEC 申报 ↗ |
| 2023-10-13 | AGENUS INC | 买入 (P) | Common Stock | 19,373 | USD 1.10 | USD 21,310 | SEC 申报 ↗ |
| 2023-10-12 | AGENUS INC | 买入 (P) | Common Stock | 3,173 | USD 1.10 | USD 3,490 | SEC 申报 ↗ |
| 2023-10-04 | AGENUS INC | 买入 (P) | Common Stock | 15,001 | USD 1.09 | USD 16,351 | SEC 申报 ↗ |
| 2023-08-29 | AGENUS INC | 买入 (P) | Common Stock | 29,678 | USD 1.52 | USD 45,111 | SEC 申报 ↗ |
| 2023-08-28 | AGENUS INC | 买入 (P) | Common Stock | 12,808 | USD 1.45 | USD 18,572 | SEC 申报 ↗ |
| 2023-08-24 | AGENUS INC | 买入 (P) | Common Stock | 170,244 | USD 1.54 | USD 262,176 | SEC 申报 ↗ |
| 2023-05-11 | AGENUS INC | 买入 (P) | Common Stock | 23,361 | USD 1.43 | USD 33,406 | SEC 申报 ↗ |
| 2023-05-10 | AGENUS INC | 买入 (P) | Common Stock | 22,065 | USD 1.51 | USD 33,318 | SEC 申报 ↗ |
| 2023-05-05 | AGENUS INC | 买入 (P) | Common Stock | 100,200 | USD 0.95 | USD 95,250 | SEC 申报 ↗ |
| 2023-05-04 | AGENUS INC | 买入 (P) | Common Stock | 21,473 | USD 1.22 | USD 26,197 | SEC 申报 ↗ |
| 2023-05-03 | AGENUS INC | 买入 (P) | Common Stock | 128,689 | USD 1.08 | USD 138,984 | SEC 申报 ↗ |
| 2023-05-02 | ARMEN GARO H | 买入 (P) | Common Stock | 100,000 | USD 0.95 | USD 95,000 | SEC 申报 ↗ |
| 2022-07-19 | WIINBERG ULF | 买入 (P) | Common Stock | 16,661 | USD 1.39 | USD 23,159 | SEC 申报 ↗ |
| 2022-07-18 | WIINBERG ULF | 买入 (P) | Common Stock | 3,339 | USD 1.33 | USD 4,441 | SEC 申报 ↗ |
Form 4 申报证据
28 transaction lines in the latest 365-day window; 121 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-12 | Buell Jennifer | 卖出 (S) | Common Stock | 6,938 | USD 10.56 | USD 73,265 | SEC 申报 ↗ |
| 2026-10-11 | Buell Jennifer | 期权行权/转换 (M) | Common Stock | 23,191 | USD — | USD — | SEC 申报 ↗ |
| 2026-09-01 | WIINBERG ULF | 奖励/授予 (A) | Common Stock | 1,279 | USD 10.95 | USD 14,005 | SEC 申报 ↗ |
展开近期 Form 4 证据 (25 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-12 | Buell Jennifer | 卖出 (S) | Common Stock | 6,938 | USD 10.56 | USD 73,265 | SEC 申报 ↗ |
| 2026-10-11 | Buell Jennifer | 期权行权/转换 (M) | Common Stock | 23,191 | USD — | USD — | SEC 申报 ↗ |
| 2026-09-01 | WIINBERG ULF | 奖励/授予 (A) | Common Stock | 1,279 | USD 10.95 | USD 14,005 | SEC 申报 ↗ |
| 2026-09-01 | Ryan Barbara | 奖励/授予 (A) | Common Stock | 1,622 | USD 10.95 | USD 17,761 | SEC 申报 ↗ |
| 2026-09-01 | Holcomb John Bradley | 奖励/授予 (A) | Common Stock | 1,233 | USD 10.95 | USD 13,501 | SEC 申报 ↗ |
| 2026-09-01 | Corvese Brian | 奖励/授予 (A) | Common Stock | 1,633 | USD 10.95 | USD 17,881 | SEC 申报 ↗ |
| 2026-09-01 | Behner Peter | 奖励/授予 (A) | Common Stock | 1,485 | USD 10.95 | USD 16,261 | SEC 申报 ↗ |
| 2026-06-04 | Ryan Barbara | 卖出 (S) | Common Stock | 1,500 | USD 12.76 | USD 19,140 | SEC 申报 ↗ |
| 2026-06-01 | WIINBERG ULF | 奖励/授予 (A) | Common Stock | 1,131 | USD 12.38 | USD 14,002 | SEC 申报 ↗ |
| 2026-06-01 | Ryan Barbara | 奖励/授予 (A) | Common Stock | 1,434 | USD 12.38 | USD 17,753 | SEC 申报 ↗ |
| 2026-06-01 | Holcomb John Bradley | 奖励/授予 (A) | Common Stock | 1,091 | USD 12.38 | USD 13,507 | SEC 申报 ↗ |
| 2026-06-01 | Corvese Brian | 奖励/授予 (A) | Common Stock | 1,444 | USD 12.38 | USD 17,877 | SEC 申报 ↗ |
| 2026-06-01 | Behner Peter | 奖励/授予 (A) | Common Stock | 1,313 | USD 12.38 | USD 16,255 | SEC 申报 ↗ |
| 2026-03-10 | Ryan Barbara | 卖出 (S) | Common Stock | 1,300 | USD 15.40 | USD 20,019 | SEC 申报 ↗ |
| 2026-03-09 | Ryan Barbara | 卖出 (S) | Common Stock | 200 | USD 10.17 | USD 2,034 | SEC 申报 ↗ |
| 2026-03-02 | Ryan Barbara | 卖出 (S) | Common Stock | 100 | USD 10.83 | USD 1,083 | SEC 申报 ↗ |
| 2026-02-27 | Ryan Barbara | 卖出 (S) | Common Stock | 400 | USD 10.86 | USD 4,344 | SEC 申报 ↗ |
| 2026-01-02 | Buell Jennifer | 代扣税 (F) | Common Stock | 10,024 | USD 11.12 | USD 111,467 | SEC 申报 ↗ |
| 2026-01-02 | Buell Jennifer | 奖励/授予 (A) | Common Stock | 31,474 | USD 11.12 | USD 349,991 | SEC 申报 ↗ |
| 2025-12-01 | WIINBERG ULF | 奖励/授予 (A) | Common Stock | 1,263 | USD 11.09 | USD 14,007 | SEC 申报 ↗ |
| 2025-12-01 | Ryan Barbara | 奖励/授予 (A) | Common Stock | 1,601 | USD 11.09 | USD 17,755 | SEC 申报 ↗ |
| 2025-12-01 | Kadlec Robert Peter | 奖励/授予 (A) | Common Stock | 1,218 | USD 11.09 | USD 13,508 | SEC 申报 ↗ |
| 2025-12-01 | Holcomb John Bradley | 奖励/授予 (A) | Common Stock | 1,128 | USD 11.09 | USD 12,510 | SEC 申报 ↗ |
| 2025-12-01 | Corvese Brian | 奖励/授予 (A) | Common Stock | 1,612 | USD 11.09 | USD 17,877 | SEC 申报 ↗ |
| 2025-12-01 | Behner Peter | 奖励/授予 (A) | Common Stock | 1,466 | USD 11.09 | USD 16,258 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | INKT |
| CIK | 0001840229 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 121 transaction lines from 2021-10-19 to 2026-10-12 17 P purchase lines · 10 S sale lines · 94 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.